Overview
MAIA market data
Price History
MAIA price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.70 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.27 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.87 – $3.19 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $85.7M · P/B 23.85.
Company News
MAIA Biotechnology Q2 EPS $(0.13) Misses $(0.11) EstimateBenzinga · Aug 10, 2026, 1:06 PM
MAIA Biotechnology Reports 90.5% Disease Control Rate In Phase 2 THIO-101 Clinical Trial Of Ateganosine For Advanced Non-Small Cell Lung CancerBenzinga · Jul 8, 2026, 2:01 PM
MAIA Biotechnology Completes Global Enrollment In Part C Of Its Phase 2 THIO-101 Expansion Study Of Ateganosine To Treat Advanced Non-Small Cell Lung CancerBenzinga · Jun 25, 2026, 12:15 PM
MAIA Biotechnology Opens Enrollment For Phase 2 Expansion Trial Of MAIA's Lead Investigational Telomere-Targeting Agent Ateganosine As A Third-Line Treatment For Non-Small Cell Lung CancerBenzinga · Jun 18, 2026, 12:45 PM
MAIA Biotechnology Provides A Patient Enrollment Update For Its Ongoing Pivotal Phase 3 Trial, THIO-104; 29 Patients Have Been Dosed Among 34 Activated Trial Sites In 6 Foreign CountriesBenzinga · Jun 4, 2026, 1:55 PM
MAIA Biotechnology Insiders Founder/CEO Vlad Vitoc, M.D. And Director Stan V. Smith, Ph.D. Increase Ownership Position Through Open Market Purchases Of ~147,700 Shares Worth ~$201KBenzinga · Jun 2, 2026, 1:54 PM
MAIA Biotechnology Announces That It Delivered A Poster Presentation Featuring The Methodology And Study Design For Its Pivotal Phase 3 Clinical Trial On May 31 At The 2026 Annual Meeting Of The American Society Of Clinical OncologyBenzinga · Jun 1, 2026, 12:05 PM
8-K filing — MAIA Biotechnology, Inc. (MAIA)SEC EDGAR · May 14, 2026, 9:02 PM